How did Ovid's Q4 2024 expenses impact its operating profit?

Ovid Therapeutics' Q4 2024 financials show a negative operating income of $10.72 million, which indicates that the company's expenses had a significant impact on its operating profit, pushing it into the red for that quarter. |code|Ticker|Name|Date|Operating Income|Operating Expenses|market_code| |---|---|---|---|---|---|---| |OVID|OVID.O|Ovid Therapeutics|2024 Q1|-1.7417E7||185| |OVID|OVID.O|Ovid Therapeutics|2024 Q2|-2.0517E7||185| |OVID|OVID.O|Ovid Therapeutics|2024 Q3|-1.3226E7||185| |OVID|OVID.O|Ovid Therapeutics|2024 Q4|-1.0722E7||185|